Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy

An interview with Yasmin Civil MD PhD, UMC Hospital, Amsterdam, Netherlands. MILAN, Italy—Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil MD PhD from the UMC Hospital in Amsterdam, who reported five-year results from the ABLATIVE trial of pre-operative MRI-guided single dose partial breast irradiation to the 14th European Breast Cancer Conference. Partial breast irradiation, given before breast-conserving surgery, achieved durable pathologic complete remissions in low-risk breast cancer, and even held out the prospect of surgery-free treatment for some patients. After giving her talk in Milan, Dr. Civil discussed the details of the ABLATIVE study findings with Peter Goodwin: AUDIO JOURNAL OF ONCOLOGY Podcast: IN:  (PETER GOODWIN) “If you are treating …… …OUT:  …… for the Audio Journal of Oncology, I’m Peter Goodwin. (9:13sec)  ABSTRACT:  https://www.ejcancer.com/article/S0959-8049(24)00203-X/abstract#%20 https://www.audiomedica.com/wp-content/2025/09/250908-Yasmin-Civil-Pre-Operative-Partial-Breast-Irradiation-Marked-Benefit-in-Low-Risk-Breast-Cancer-AJO-PRODUCTION-MASTER-copy.mp3 Yasmin Civil MD PhD “Pre-operative magnetic resonance guided single dose partial breast irradiation: five-year results of the ABLATIVE trial” BACKGROUND: Preoperative partial breast irradiation (PBI) can result in decreased irradiated volumes compared with postoperative PBI and may therefore lead to lesstoxicity and improved cosmetic outcome. In the multicenter ABLATIVE trial (NCT02316561), 15/36 patients achieved pathologic complete response 6–8 months after preoperative single-dose PBI. We now present long-term outcomes of preoperative single-dose PBI and breast conserving surgery (BCS) including late toxicity, tumor recurrence, survival, cosmetic outcome and quality of life in low-risk breast cancer patients. PROTOCOL: The ABLATIVE-2 trial is a multicenter prospective single-arm trial using single-dose ablative PBI in low-risk breast cancer patients. Patients ≥ 50 years with non-lobular invasive breast cancer ≤ 2 cm, grade 1 or 2, estrogen receptor-positive, HER2-negative, and tumor-negative sentinel node procedure are eligible. PBI treatment planning performed using a radiotherapy planning CT and -MRI in treatment position. The treatment delivery on a conventional or MR-guided linear accelerator. The prescribed radiotherapy dose is a single dose of 20 Gy to the tumor, and 15 Gy to the 2 cm of breast tissue surrounding the tumor. Follow-up MRIs, scheduled at baseline, 2 weeks, 3, 6, 9, and 12 months after PBI, are combined with liquid biopsies to identify biomarkers for pCR prediction. BCS performed 12 months after radiotherapy or after 6 months, if MRI does not show a radiologic complete response. The primary endpoint is the pCR rate after PBI. Secondary endpoints are radiologic response, toxicity, quality of life, cosmetic outcome, patient distress, oncological outcomes, and the evaluation of biomarkers in liquid biopsies and tumor tissue.  

There are no comments yet.

Please log in to write the first comment.